Carcinogenesis Advance Access originally published online on December 20, 2006
Carcinogenesis 2007 28(5):940-946; doi:10.1093/carcin/bgl249
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press 2006.
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
* To whom correspondence should be addressed. Tel: +301 496 9067; Fax: +301 496 8409; Email: fjgonz{at}helix.nih.gov
The farnesoid X receptor (FXR) controls the synthesis and transport of bile acids (BAs). Mice lacking expression of FXR, designated Fxr-null, have elevated levels of serum and hepatic BAs and an increase in BA pool size. Surprisingly, at 12 months of age, male and female Fxr-null mice had a high incidence of degenerative hepatic lesions, altered cell foci and liver tumors including hepatocellular adenoma, carcinoma and hepatocholangiocellular carcinoma, the latter of which is rarely observed in mice. At 3 months, Fxr-null mice had increased expression of the proinflammatory cytokine IL-1ß mRNA and elevated ß-catenin and its target gene c-myc. They also had increased cell proliferation as revealed by increased PCNA mRNA and BrdU incorporation. These studies reveal a potential role for FXR and BAs in hepatocarcinogenesis.
Abbreviations: BA, bile acid; FXR, farnesoid X receptor; HCC, hepatocellular carcinoma; HSC, hepatic stellate cell; PBS, phosphate-buffered saline; qPCR, quantitative polymerase chain reaction; RT, room temperature; WT, wild-type
Received August 25, 2006; revised November 27, 2006; accepted December 7, 2006.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. Mencarelli, B. Renga, M. Migliorati, S. Cipriani, E. Distrutti, L. Santucci, and S. Fiorucci The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis J. Immunol., November 15, 2009; 183(10): 6657 - 6666. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Servitja, M. Pignatelli, M. A. Maestro, C. Cardalda, S. F. Boj, J. Lozano, E. Blanco, A. Lafuente, M. I. McCarthy, L. Sumoy, et al. Hnf1{alpha} (MODY3) Controls Tissue-Specific Transcriptional Programs and Exerts Opposed Effects on Cell Growth in Pancreatic Islets and Liver Mol. Cell. Biol., June 1, 2009; 29(11): 2945 - 2959. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R.M. Maran, A. Thomas, M. Roth, Z. Sheng, N. Esterly, D. Pinson, X. Gao, Y. Zhang, V. Ganapathy, F. J. Gonzalez, et al. Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 469 - 477. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation Physiol Rev, January 1, 2009; 89(1): 147 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Modica, S. Murzilli, L. Salvatore, D. R. Schmidt, and A. Moschetta Nuclear Bile Acid Receptor FXR Protects against Intestinal Tumorigenesis Cancer Res., December 1, 2008; 68(23): 9589 - 9594. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Eloranta and G. A. Kullak-Ublick The Role of FXR in Disorders of Bile Acid Homeostasis Physiology, October 1, 2008; 23(5): 286 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, L. Wang, S. Zhang, J. Lin, S. Zhang, M. A. Feitelson, H. Gao, and M. Zhu Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses Carcinogenesis, June 1, 2008; 29(6): 1207 - 1214. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kim, S.-H. Ahn, T. Inagaki, M. Choi, S. Ito, G. L. Guo, S. A. Kliewer, and F. J. Gonzalez Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine J. Lipid Res., December 1, 2007; 48(12): 2664 - 2672. [Abstract] [Full Text] [PDF] |
||||







